Anti-VEGF therapy changed retinal medicine in a way few treatments ever do. Before these drugs arrived, wet macular degeneration usually meant relentless central vision loss. Now many patients keep vision stable for years, and some gain vision they were actively losing. That is a major shift. It changed what retina specialists can realistically offer people with some of the most common sight-threatening diseases.

---

Which conditions are treated with anti-VEGF?

Wet age-related macular degeneration

Wet age-related macular degeneration (AMD) is the most common reason anti-VEGF therapy is prescribed. In wet AMD, abnormal vessels grow beneath the retina and leak into the macula, causing distortion, blur, and often rapid loss of central vision. Before anti-VEGF treatment, the outlook was usually poor. With regular injections, many patients now maintain useful vision for years, and a meaningful minority improve.

Diabetic macular edema

In people with diabetes, damaged retinal blood vessels can leak fluid into the macula. This swelling, called diabetic macular edema (DME), blurs the central vision needed for reading, driving, and detailed work. Anti-VEGF injections are first-line treatment when the center of the macula is involved. They work best alongside solid blood sugar and blood pressure control, because the injection treats the eye while the systemic disease keeps applying pressure in the background.

Diabetic retinopathy

In advanced diabetic retinopathy, abnormal new vessels can grow across the retinal surface and into the vitreous. Left alone, they can bleed or contribute to tractional retinal detachment. Anti-VEGF injections can make these vessels regress. That matters because the treatment is addressing not just swelling, but the underlying proliferative drive.

Retinal vein occlusion

When a retinal vein becomes blocked, fluid and blood leak into the surrounding tissue. Retinal vein occlusion often causes sudden, painless blur or vision loss. Anti-VEGF injections are the main treatment when macular edema is threatening vision, whether the blockage is in a branch vein or the central retinal vein.

Other uses

Anti-VEGF therapy is also used for selected cases of myopic choroidal neovascularization and as an adjunct in some retinal surgeries. The list of uses has expanded over time, though not every leaky or swollen retina responds equally well. The drug class is powerful, but it is not magic.

---

The medications: what’s available

Several anti-VEGF agents are used in ophthalmology. They share the same core purpose but differ in structure, durability, cost, and how often they can realistically be given.

Ranibizumab (Lucentis)

Ranibizumab was the first anti-VEGF medication developed specifically for use inside the eye. It became the reference treatment in the landmark trials that established anti-VEGF therapy as standard care for wet AMD and diabetic macular edema. It still has a strong track record.

Aflibercept (Eylea)

Aflibercept acts as a VEGF trap, binding multiple VEGF family members with high affinity. It is approved for wet AMD, DME, and retinal vein occlusion. In some patients it allows longer intervals between injections than ranibizumab, though the real-world answer is less tidy than the brochures suggest. Some eyes extend nicely. Others do not.

Bevacizumab (Avastin)

Bevacizumab is a cancer drug that was found to work well in the eye. It is widely used off-label because it is dramatically less expensive than purpose-built ophthalmic agents. Large studies have shown it to be broadly comparable to ranibizumab for wet AMD. Choosing between agents often comes down to a mix of anatomy, response pattern, access, and cost.

Newer agents: faricimab and brolucizumab

Faricimab (Vabysmo) targets both VEGF-A and a second pathway, Ang-2, with strong trial results in wet AMD and DME. Brolucizumab (Beovu) was designed to allow longer treatment intervals in some patients. Both reflect the same goal: reduce treatment burden without giving up control of the disease. That is appealing, but individual response still decides everything.

---

What to expect from the procedure

Before the injection

Anti-VEGF injections are done in a clinic, not an operating room. The full visit usually takes less than 15 minutes. No fasting is needed. The eye is typically dilated, numbed with anesthetic drops or gel, and cleaned carefully with antiseptic to reduce the risk of infection. That cleaning step matters more than patients realize.

The injection itself

A very fine needle delivers a small amount of medication into the vitreous cavity, the gel-filled space behind the lens. Most patients describe pressure, not sharp pain. A brief sting, a flash of light, or a strange awareness that something just happened is common. The injection itself takes seconds.

Afterwards

The eye may feel scratchy, mildly sore, or look red for a day or two. Vision can be temporarily blurred. Small floaters or bubbles right after the injection are common and usually settle within 24 to 48 hours. Avoid rubbing the eye, and avoid swimming for a few days. Most people are back to usual activities the next day.

---

How often are injections needed?

Anti-VEGF therapy is rarely a one-time treatment. Most retinal diseases treated this way are chronic, which means the management plan usually stretches over months or years.

For wet AMD, treatment often starts with three monthly injections, then moves into a maintenance phase where the interval is adjusted based on how the retina looks and how the patient is doing. Some people need injections every four to six weeks for a long time. Others can extend to every two or three months, sometimes longer. Stopping altogether often allows the disease to reactivate. DME and retinal vein occlusion are managed in a similar fashion, with OCT scans helping guide each decision.

The schedule can feel relentless. It is worth saying that out loud if it is affecting work, transportation, or quality of life, because sometimes the regimen can be adjusted and sometimes it cannot. Knowing which is which helps.

---

For further reading: Injections to treat eye conditions, National Eye Institute and Age-related macular degeneration, American Academy of Ophthalmology. To explore the latest research on retinal conditions and anti-VEGF treatments, visit our Retina subspecialty section.